| Chemical Properties | Back Directory | [Boiling point ]
1143.9±65.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
1.83±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
CRWOFMLXEOYIEP-JZEPPUFONA-N | [SMILES]
C(C1=CC=NC2C=CC(OCCCN3CCN(C(=O)CN4CCN(CCN(CC(=O)O)CCN(CC(=O)O)CC4)CC(=O)O)CC3)=CC1=2)(=O)NCC(N1CCC[C@H]1C#N)=O |&1:56,r| |
| Hazard Information | Back Directory | [Uses]
FAPI-2 is a type of small molecule fibroblast activation protein inhibitor (FAPI) that targets the fibroblast activation protein (FAP) and has an inhibitory effect. This specific targeting ability makes FAPI-2 an effective tumor imaging agent, which can be used in cancer research. FAPI-2 can be used to synthesize 68Ga-FAPI-2 (a PET tracer)[1][2][3][4]. | [References]
[1] Giesel FL, et al. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019 Mar;60(3):386-392. DOI:10.2967/jnumed.118.215913
[2] Moon ES, et al. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Am J Nucl Med Mol Imaging. 2021 Dec 15;11(6):476-491. PMID:35003886
[3] Li M, et al. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2844-2868. doi: 10.1007/s00259-022-05706-y. Epub 2022 Jan 31. Erratum in: Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):3007. DOI:10.1007/s00259-022-05706-y
[4] Sanjana Ballal, et al. First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer. Clin Nucl Med. 2022 Jun 1;47(6):e444-e445. DOI:10.1097/RLU.0000000000004164 |
|
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 |
| Website: |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|